Pulsar Helium Inc. (AIM: PLSR, TSXV: PLSR, OTCQB: PSRHF) (“ Pulsar ” or the “ Company ”), a leading helium project development company, is pleased to announce the successful completion of the ...
Hydro and Northvolt have signed an agreement where Hydro will acquire the remaining shares in the battery recycler Hydrovolt for NOK 78 million. Hydro is increasing its ownership in Hydrovolt from 72 ...
Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto ® (sacubitril/valsartan) combination ...
Idorsia will call a bondholder meeting in accordance with articles 1164 et seqq. of the Swiss Code of Obligations and will propose to the bondholders to modify the terms of the Bonds to, among others, ...
Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights ...
W&T Offshore, Inc. (NYSE: WTI) (“W&T Offshore” or the “Company”) today announced its intention to offer, subject to market and other conditions, $350 million in aggregate principal amount of senior ...
In January 2025, SUS ENVIRONMENT launches new global brand identity. This renewal improves the brand image and enriches the brand connotation, bolstering its commitment to global sustainable ...
SINGAPORE, Jan. 13, 2025 /PRNewswire/ -- Pollo AI, an innovative leader in AI-powered video generation, today announced the launch of a new feature that allows users to select from a range of ...
NYP will be the first polytechnic to receive the official certification of a Dolby Atmos 7.1.4 Surround Audio Studio – to ...
Under the terms of the agreement, Biohaven is responsible for the preclinical ADC generation of three Merus bispecific antibodies under mutually agreed research plans. The agreement includes two Merus ...
Caribou has initiated the GALLOP Phase 1 clinical trial, an open-label, multicenter clinical trial designed to evaluate a single infusion of CB-010 in adult patients with LN and ERL. CB-011, a ...
Following closing of its transaction with Telix Pharmaceuticals, ImaginAb, Inc. will be focused on developing its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials ...